Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey J Raizer

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|August 18, 2015
The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapyLijie Zhai, Mahua Dey, Kristen L Lauing, et al.
Molecular Cancer Therapeutics|October 15, 2014
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplificationYasuyuki Yoshida, Tomoko Ozawa, Tsun-Wen Yao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcomePatrick G Morris, Denise D Correa, Joachim Yahalom, et al.
Neuro-Oncology|November 12, 2019
Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomasMichael R Drumm, Karan S Dixit, Sean Grimm, et al.
Annals of Neurology|April 6, 2006
International study on low-grade primary central nervous system lymphomaKristoph Jahnke, Agnieszka Korfel, Brian Patrick O'Neill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2023
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction AdenocarcinomaSamuel J Klempner, Keun-Wook Lee, Kohei Shitara, et al.
Neuro-Oncology|August 8, 2018
Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progressionRaymond Y Huang, Prashin Unadkat, Wenya Linda Bi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2008
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiformeDavid A Reardon, Karen L Fink, Tom Mikkelsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2022
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent GlioblastomaChristina I Tsien, Stephanie L Pugh, Adam P Dicker, et al.
Journal of Oncology Practice|December 4, 2014
Economics of Malignant Gliomas: A Critical ReviewJeffrey J Raizer, Karen A Fitzner, Daniel I Jacobs, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|August 18, 2015
The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapyLijie Zhai, Mahua Dey, Kristen L Lauing, et al.
Molecular Cancer Therapeutics|October 15, 2014
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplificationYasuyuki Yoshida, Tomoko Ozawa, Tsun-Wen Yao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcomePatrick G Morris, Denise D Correa, Joachim Yahalom, et al.
Neuro-Oncology|November 12, 2019
Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomasMichael R Drumm, Karan S Dixit, Sean Grimm, et al.
Annals of Neurology|April 6, 2006
International study on low-grade primary central nervous system lymphomaKristoph Jahnke, Agnieszka Korfel, Brian Patrick O'Neill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2023
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction AdenocarcinomaSamuel J Klempner, Keun-Wook Lee, Kohei Shitara, et al.
Neuro-Oncology|August 8, 2018
Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progressionRaymond Y Huang, Prashin Unadkat, Wenya Linda Bi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2008
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiformeDavid A Reardon, Karen L Fink, Tom Mikkelsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2022
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent GlioblastomaChristina I Tsien, Stephanie L Pugh, Adam P Dicker, et al.
Journal of Oncology Practice|December 4, 2014
Economics of Malignant Gliomas: A Critical ReviewJeffrey J Raizer, Karen A Fitzner, Daniel I Jacobs, et al.
Pageof 8